1. Advanced Lung Cancers: What's on the Horizon?

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. BIRCH Efficacy Update For Atezolizumab

4. Updates From KEYNOTE-021 Cohort G

5. Updates From KEYNOTE-024

6. CheckMate 012: 3-Year Update for Nivolumab

7. CheckMate 153: Duration of Nivolumab

8. ECHO-202/KEYNOTE-037: Epacadostat Plus Pembrolizumab

9. PACIFIC: Durvalumab

10. Pembrolizumab for Oligometastatic NSCLC

11. Advanced Lung Cancers: What's on the Horizon?

12. Introduction

13. CheckMate 032: Efficacy Data With Nivo ± Ipi From Nonrandomized Cohorts

14. CheckMate 032: Randomized Data

15. KEYNOTE-028: Second-Line Pembrolizumab

16. CheckMate 032: Safety

17. PD-L1 Frequency and Subgroup Responses

18. TMB Subgroups

19. RovaT: Trials In Progress

20. Advanced Lung Cancers: What's on the Horizon?

21. PD-1/PD-L1 Inhibitors in Salvage Mesothelioma

22. PD-1 Plus CTLA4 Combinations

23. 2017 NCCN Update

24. Selected Ongoing Salvage Immunotherapy Trials

25. Selected Ongoing Frontline Immunotherapy Trials

26. Advanced Lung Cancers: What's on the Horizon?

27. Proof of Principle From Melanoma

28. Proof of Principle From Melanoma (cont)

29. Rationale and Efficacy in Lung Cancer

30. Impact of Brain Metastases on Outcomes With Immunotherapy

31. Italian Expanded Access Programme

32. Intracranial Responses With Nivolumab

33. Retrospective Analysis at Chiba Cancer Center

34. Concluding Remarks

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)

38. Abbreviations (cont)